Document is current
Any future updates will be listed below
-
Authors
Oom, Aaron L.
Wilson, Kesi K.
Rettig, Stephanie
Tuen, Michael
Samanovic, Marie I.
Kottkamp, Angelica C.
Herati, Ramin Sedaghat
Duerr, Ralf
Mulligan, Mark J.
,
Abdulai, Abdul
Arciuolo, Robert
Callahan, Jaqueline
Carmody, Ellie
Davis, Tamia
Dontino, Amanda
Edwin, Aimee
Engelson, Celia
Fleming, Andrew
Frank, Olivia
Geesey, Emily
Goins, Shelby
Guerra, Victoria
Guevarra, Erika
Haiken, Sarah
Henry, Aaliyah
Jano, Kathryn
Karmacharya, Trishala
Knutsen, Dorothy
Noriega, Irma
Null, Maria
Nweke, Samuel
Parameswaran, Lalitha
Pitts, Robert
Randhawa, Gurchetan
Rodriguez, Miguel
Suman, Pamela
Talanki, Apoorva
Tasissa, Meron
Swindell, Kathryn
Wagner, Julia
Wilson, Jimmy P.
Yip, Samantha
Yonatan, Miilani
Youn, Heekoung Allison
Zhao, Lisa
-
Funding
Funding for this research was provided by:
National Institutes of Health (T32AI100853)
National Institutes of Health (AI148574)
Blavatnik Family Foundation
New York City Department of Health and Mental Hygiene
NYU Grossman School of Medicine
- License Information
-
More Information
Article History
Received: 10 November 2025
Accepted: 21 April 2026
First Online: 7 May 2026
Competing interests
: M.J.M. reported potential competing interests: laboratory research and clinical trials contracts for vaccines or MAB with Lilly, Pfizer, and Sanofi; research grant funding from USG/HHS/NIH for vaccine and MAB clinical trials; personal fees for Scientific Advisory Board service from Hillevax, Merck, Meissa Vaccines, Sanofi, Pfizer, and GSK.
